Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T D Sandahl

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Alimentary Pharmacology & Therapeutics|May 18, 2012
Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosisH Grønbaek, T D Sandahl, C Mortensen, et al.
European Journal of Clinical Nutrition|February 25, 2011
Do all patients with type 2 diabetes need breakfast?T Parkner, J K Nielsen, T D Sandahl, et al.
Alimentary Pharmacology & Therapeutics|April 11, 2016
The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosisT D Sandahl, R McGrail, H J Møller, et al.
Alimentary Pharmacology & Therapeutics|December 22, 2017
Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocationF Rainer, A Horvath, T D Sandahl, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Alimentary Pharmacology & Therapeutics|May 18, 2012
Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosisH Grønbaek, T D Sandahl, C Mortensen, et al.
European Journal of Clinical Nutrition|February 25, 2011
Do all patients with type 2 diabetes need breakfast?T Parkner, J K Nielsen, T D Sandahl, et al.
Alimentary Pharmacology & Therapeutics|April 11, 2016
The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosisT D Sandahl, R McGrail, H J Møller, et al.
Alimentary Pharmacology & Therapeutics|December 22, 2017
Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocationF Rainer, A Horvath, T D Sandahl, et al.
Pageof 1